Microencapsulated chitosan nanoparticles for pulmonary protein delivery: in vivo evaluation of insulin-loaded formulations.
暂无分享,去创建一个
C. Remuñán-López | B. Seijo | S. Al-Qadi | A. Grenha | D. Carrión-Recio | C Remuñán-López | B Seijo | S Al-Qadi | A Grenha | D Carrión-Recio | Sonia Al-Qadi
[1] Y. Kawashima,et al. Mucoadhesive nanoparticulate systems for peptide drug delivery. , 2001, Advanced drug delivery reviews.
[2] Simon Cawthorne,et al. Particle engineering techniques for inhaled biopharmaceuticals. , 2006, Advanced drug delivery reviews.
[3] S. Giosué,et al. Aerosolized interferon-alpha treatment in patients with multi-drug-resistant pulmonary tuberculosis. , 2000, European cytokine network.
[4] N. He,et al. Chitosan/sodium tripolyphosphate nanoparticles: preparation, characterization and application as drug carrier. , 2009, Journal of biomedical nanotechnology.
[5] C. Remuñán-López,et al. Microencapsulated chitosan nanoparticles for lung protein delivery. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[6] V. Préat,et al. Confocal imaging of rat lungs following intratracheal delivery of dry powders or solutions of fluorescent probes. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[7] K. Amighi,et al. Formulation strategy and use of excipients in pulmonary drug delivery. , 2010, International journal of pharmaceutics.
[8] M. Alonso,et al. Chitosan/cyclodextrin nanoparticles as macromolecular drug delivery system. , 2007, International journal of pharmaceutics.
[9] A. Misra,et al. A preliminary pharmacokinetic study of liposomal leuprolide dry powder inhaler: A technical note , 2005, AAPS PharmSciTech.
[10] Wei Yang,et al. Inhaled nanoparticles--a current review. , 2008, International journal of pharmaceutics.
[11] E. Crandall,et al. Hydrophilic solute transport across rat alveolar epithelium. , 1989, Journal of applied physiology.
[12] J. Patton,et al. Mechanisms of macromolecule absorption by the lungs , 1996 .
[13] V. Cardile,et al. Chitosan microspheres for intrapulmonary administration of moxifloxacin: interaction with biomembrane models and in vitro permeation studies. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[14] Y Ikada,et al. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. , 1988, Biomaterials.
[15] Yu Zhang,et al. Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. , 2004, International journal of pharmaceutics.
[16] Qun Wang,et al. Solid lipid nanoparticles as insulin inhalation carriers for enhanced pulmonary delivery. , 2009, Journal of biomedical nanotechnology.
[17] J. Evans,et al. The distribution of dust in the rat lung following administration by inhalation and by single intratracheal instillation. , 1985, Environmental research.
[18] Monireh Jalalipour,et al. Effect of dimethyl-beta-cyclodextrin concentrations on the pulmonary delivery of recombinant human growth hormone dry powder in rats. , 2008, Journal of pharmaceutical sciences.
[19] B. Forbes,et al. In vivo and in vitro characterization of novel microparticulates based on hyaluronan and chitosan hydroglutamate , 2001, AAPS PharmSciTech.
[20] H Salem,et al. Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. , 2000, Toxicological sciences : an official journal of the Society of Toxicology.
[21] G. P. Martin,et al. Chitosan nanoparticles are compatible with respiratory epithelial cells in vitro. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[22] R. Löbenberg,et al. Targeted delivery of nanoparticles for the treatment of lung diseases. , 2008, Advanced drug delivery reviews.
[23] Véronique Préat,et al. Alveolar macrophages are a primary barrier to pulmonary absorption of macromolecules. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[24] G. van Amerongen,et al. Administration of an insulin powder to the lungs of cynomolgus monkeys using a Penn Century insufflator. , 2004, International journal of pharmaceutics.
[25] H. Junginger,et al. Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[26] C. Remuñán-López,et al. Enhancement of Nasal Absorption of Insulin Using Chitosan Nanoparticles , 1999, Pharmaceutical Research.
[27] Kyle E Broaders,et al. In vitro analysis of acetalated dextran microparticles as a potent delivery platform for vaccine adjuvants. , 2010, Molecular pharmaceutics.
[28] H. Folkesson,et al. Mechanisms of alveolar protein clearance in the intact lung. , 2004, American journal of physiology. Lung cellular and molecular physiology.
[29] O. Raabe,et al. Factors influencing the deposition of inhaled particles. , 1976, Environmental health perspectives.
[30] A. Bernkop‐Schnürch,et al. Oral peptide drug delivery: polymer-inhibitor conjugates protecting insulin from enzymatic degradation in vitro. , 2000, Biomaterials.
[31] J. Kaur,et al. Inhalable microparticles containing large payload of anti-tuberculosis drugs. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[32] Shohei Sugimoto,et al. Surface-modified PLGA nanosphere with chitosan improved pulmonary delivery of calcitonin by mucoadhesion and opening of the intercellular tight junctions. , 2005, Journal of controlled release : official journal of the Controlled Release Society.
[33] de las Nieves FJ,et al. Colloidal Stability of Polymer Colloids with Variable Surface Charge. , 1999, Journal of colloid and interface science.
[34] P. Garidel,et al. Conformational analysis of protein secondary structure during spray-drying of antibody/mannitol formulations. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[35] J. S. Lobo,et al. Effect of hydroxypropyl methylcellulose and hydrogenated castor oil on naproxen release from sustained-release tablets , 2001, AAPS PharmSciTech.
[36] A. Clark,et al. Design of fine particles for pulmonary drug delivery , 2007, Expert opinion on drug delivery.
[37] N. Rooijen,et al. The macrophage as target or obstacle in liposome-based targeting strategies , 1998 .
[38] J. Hanes,et al. Poly(ether-anhydride) dry powder aerosols for sustained drug delivery in the lungs. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[39] M. Davies,et al. The surface characterisation and comparison of two potential sub-micron, sugar bulking excipients for use in low-dose, suspension formulations in metered dose inhalers. , 2008, International journal of pharmaceutics.
[40] Fakhrul Ahsan,et al. Absorption enhancers in pulmonary protein delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.
[41] C. Remuñán-López,et al. Chitosan nanoparticle-loaded mannitol microspheres: structure and surface characterization. , 2007, Biomacromolecules.
[42] V. Préat,et al. Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[43] I. El-Sherbiny,et al. Swellable microparticles as carriers for sustained pulmonary drug delivery. , 2010, Journal of pharmaceutical sciences.
[44] Waseem Kaialy,et al. Engineered mannitol as an alternative carrier to enhance deep lung penetration of salbutamol sulphate from dry powder inhaler. , 2010, Colloids and surfaces. B, Biointerfaces.
[45] J. Brain. Inhalation, deposition, and fate of insulin and other therapeutic proteins. , 2007, Diabetes technology & therapeutics.
[46] M. L. La Rotonda,et al. Insulin-loaded PLGA/cyclodextrin large porous particles with improved aerosolization properties: in vivo deposition and hypoglycaemic activity after delivery to rat lungs. , 2009, Journal of controlled release : official journal of the Controlled Release Society.
[47] Lawrence X. Yu,et al. In Vitro Considerations to Support Bioequivalence of Locally Acting Drugs in Dry Powder Inhalers for Lung Diseases , 2009, The AAPS Journal.
[48] K. Juni,et al. Pulmonary Delivery of Salmon Calcitonin Dry Powders Containing Absorption Enhancers in Rats , 2004, Pharmaceutical Research.
[49] S. Anderson,et al. Beneficial effect of inhaled mannitol and cough in asthmatics with mucociliary dysfunction. , 2010, Respiratory medicine.
[50] M. Welham,et al. Spray‐dried insulin particles retain biological activity in rapid in‐vitro assay , 2001, The Journal of pharmacy and pharmacology.
[51] J. Birchall,et al. Chitosan-Modified Dry Powder Formulations for Pulmonary Gene Delivery , 2006, Pharmaceutical Research.
[52] R. Pandey,et al. Antitubercular inhaled therapy: opportunities, progress and challenges. , 2005, Journal of Antimicrobial Chemotherapy.
[53] J. Thipphawong,et al. Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. , 2003, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.
[54] E. Daviskas,et al. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers. , 2008, International journal of pharmaceutics.
[55] M. Davis,et al. Pulmonary distribution of particles given by intratracheal instillation or by aerosol inhalation. , 1976, Environmental research.
[56] M. Alonso,et al. Chitosan and Chitosan/Ethylene Oxide-Propylene Oxide Block Copolymer Nanoparticles as Novel Carriers for Proteins and Vaccines , 1997, Pharmaceutical Research.
[57] P. Artursson,et al. Chitosan and the mucosal delivery of biotechnology drugs. , 2005, Drug discovery today. Technologies.